![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novavax Expands COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India
Novavax Expands COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India
![Novavax logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Novavax-logo.gif?t=1590614250&width=430)
September 16, 2020
Maryland-based Novavax is aiming to produce 2 billion doses of its COVID-19 vaccine annually by 2021, and it has just expanded a manufacturing agreement with the Serum Institute of India, the world’s largest vaccine developer.
The institute will manufacture the antigen component of NVX-2373, making it one of five manufacturers around the world doing that for Novavax. The institute previously agreed to produce at least 1 billion doses of the Novavax vaccine for low- and middle-income countries.
Novavax President and CEO Stanley C. Erck said the company anticipates starting phase 3 efficacy trials of the vaccine around the world “in the coming weeks.”
Upcoming Events
-
21Oct